Pepdexpepdex
My Stack
№ 063

Petrelintide

Zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor.

Fat Loss
Evidence: Moderate

Petrelintide: Zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor. Petrelintide is Novo Nordisk's next-generation amylin drug, Cagrilintide's successor.

FDA ⓘ
Not approved
WADA
Not banned
Typical dose
Start 0.3 mg weekly
Half-life ⓘ
~10 days (acylated/lipidated)
Route ⓘ
Subcutaneous
Schedule
Once weekly
In plain English

Petrelintide is Novo Nordisk's next-generation amylin drug, Cagrilintide's successor. Same pathway as Cagrilintide but with weekly dosing and stronger receptor binding. In Phase 2/3 trials. Will eventually pair with Semaglutide the way CagriSema does, but as one drug.

Status & legalityWhat do these mean? →
Natty? ⓘ
Not natty
FDA ⓘ
Not approved

Investigational. Developed by Zealand Pharma (partnered with Roche). Phase 2 complete; Phase 3 planned for H2 2026. Not yet approved.

Compounding ⓘ
Investigational

In clinical trials, not yet approved for prescription.

WADA ⓘ
Not listed
Prescribed ⓘ

Trial access only.

Who it's for

  • →Trial participants in obesity studies
  • →Educational reference for the next-generation amylin pathway
  • →Followers of Zealand Pharma's metabolic pipeline

What to expect

  1. Week 1

    Appetite reduction begins. Less GI side effect profile than GLP-1 monotherapy.

  2. Week 4

    First titration step. Weight loss accruing.

  3. Week 8

    Phase 2 endpoint data showed steady cumulative loss.

Looking at Petrelintide? Your next 3 steps

  1. 1Work out your exact dose

    Vial size + BAC water turns into the exact units to draw for Petrelintide.

    Open calculator →
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide →
  3. 3Save it & ask the Coach

    A free account saves your stack; membership adds the stack-aware AI Coach.

    Create free account →

How it works (mechanism)

Next-generation amylin analog with stronger receptor binding and weekly dosing. Same pathway as Cagrilintide.

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Mild nausea
02Reduced appetite
03Constipation
04Generally cleaner profile than GLP-1 monotherapy

When NOT to use

  • ⚠MTC / MEN-2 history
  • ⚠Pancreatitis history
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Lipid panel
  • • A1C if metabolic context

Common mistakes

  • • Treating community-vendor product as trial-grade material
  • • Titrating too fast
  • • Expecting Tirzepatide-tier weight loss as monotherapy

Drug & supplement interactions

  • ⚠Same amylin-class precaution: oral medication absorption may be affected
  • ⚠Trial-only
Free, no account needed

New to Petrelintide? Grab the starter checklist.

Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if Petrelintide changes legal status. No account needed.

No spam. No selling your email. Just the checklist and the occasional reclassification alert.

AI Coach, live sample
Members only
is 250mcg of bpc enough for a knee injury?
For a knee, 250 mcg sub-q daily is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. Inject close to the joint, run it 4-6 weeks, and don't drop below 200 mcg, it tends to stop cracking the threshold reliably down there. If it hasn't moved at all by week 3, that's when adding TB-500 earns its place.
how much bac water for a 10mg reta vial?
3 mL is the standard play for a 10 mg reta vial. That's 3,333 mcg/mL, clean unit math across the titration: 2 mg = 60 units, 4 mg = 120 units, 6 mg = 180 units on a 100-unit insulin syringe. Run 2 mL instead if you want fewer, more concentrated shots (5,000 mcg/mL, so 2 mg = 40 units). Since most people titrate up over ~12 weeks, 3 mL keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Ask the Coach anything about Petrelintide or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Get the Coach, $7.99/mo →

Frequently asked

What is Petrelintide?+
Petrelintide is Novo Nordisk's next-generation amylin drug, Cagrilintide's successor. Same pathway as Cagrilintide but with weekly dosing and stronger receptor binding. In Phase 2/3 trials. Will eventually pair with Semaglutide the way CagriSema does, but as one drug.
Is Petrelintide FDA approved?+
Investigational. Developed by Zealand Pharma (partnered with Roche). Phase 2 complete; Phase 3 planned for H2 2026. Not yet approved.
Is Petrelintide legal?+
Petrelintide is not FDA-approved. It is sold by compounding pharmacies (with a prescription) and as "research only" by peptide vendors. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is Petrelintide banned by WADA?+
Petrelintide is not currently on the WADA prohibited list.
Are you still natty after taking Petrelintide?+
No. Petrelintide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Petrelintide?+
Trial access only.
What's the typical dose of Petrelintide?+
Start 0.3 mg weekly, titrate over 4-week steps. Trial doses up to 9 mg.
What are the side effects of Petrelintide?+
Common side effects include: Mild nausea; Reduced appetite; Constipation; Generally cleaner profile than GLP-1 monotherapy. Less common effects and full safety details are on the entry page.
How long until Petrelintide starts working?+
Appetite reduction begins. Less GI side effect profile than GLP-1 monotherapy.
What can you stack with Petrelintide?+
Common pairings: Standalone in current trials. Eventual pairing with Semaglutide expected (CagriSema-style). Full stacking protocol and timing on the entry page.
Where do people get Petrelintide?+
Petrelintide is most commonly sold by research-only peptide vendors and by compounding pharmacies (the latter requires a prescription). Pepdex is not a vendor, see /coa for how to verify a Certificate of Analysis before buying from any source, and /guides/scam-vendor-spotting for vendor red flags.

More in Fat Loss

№ 008
Tirzepatide

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

№ 009
Semaglutide

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 058
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.